Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$9.7 million","upfrontCash":"Undisclosed","newsHeadline":"Tetra Pharm Technologies Secures \u20ac9 Million In Series A Round to Expand R&D Operations","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Pharm Technologies Launches First Product in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Pharm Technologies Advances CB1 Antagonist, TPT0701, for Appetite Suppression into Preclinical Testing","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Tetra Pharm Technologies

    Menu

    Tetra Pharm Technologies

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Tetra Pharm Technologies

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tetra Pharm Technologies Advances CB1 Antagonist, TPT0701, for Appetite Suppression into Preclinical Testing

              Details:

              TPT0701 is a CB1 receptor antagonist, which offers a novel approach to appetite suppression aiming to provide individuals with a safe and effective means to manage their cravings. It is being evaluated in preclinical studies for the treatment of obesity.

              Lead Product(s): TPT0701

              Therapeutic Area: Nutrition and Weight Loss Product Name: TPT0701

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 08, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tetra Pharm Technologies

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tetra Pharm Technologies Launches First Product in Germany

              Details:

              Company is launching its first product, XATEPA®, on the German market. XATEPA® is based on cannabinoids, being indiacated for the treament of neuropathic pain, sclerosis and mental health disorders.

              Lead Product(s): Cannabinoid

              Therapeutic Area: Neurology Product Name: Xatepa

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tetra Pharm Technologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tetra Pharm Technologies Secures €9 Million In Series A Round to Expand R&D Operations

              Details:

              Tetra Pharm Technologies will use the net proceeds to increase its capacity in Research and Development and expand its commercial operations internationally.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $9.7 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing January 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY